Epilepsy
📧 Sign up to get email alerts when something new happens for Epilepsy.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2021-01-26FDA Approved: ZONISAMIDE — Original Application (Unichem Pharmaceuticals (USA), Inc.)
FDA approved Unichem Pharmaceuticals (USA), Inc.'s generic zonisamide product through an Abbreviated New Drug Application, confirming a gene…
-
FDA approval · 2021-01-22FDA Approved: CLONAZEPAM — Supplemental Application (Par Health USA, LLC)
The FDA approved a supplemental application for clonazepam from Par Health USA, LLC under an ANDA, signaling approval of a supplemental fili…
-
CLINICAL_TRIALS trial_result · 2021-01-22Clinical Trial Update: A Clinical Study to Investigate the Long-term Use of Lacosamide as Monotherapy in Subjects Who Completed Study SP0994 [Phase 3]
Phase 3 clinical trial update evaluating long-term lacosamide monotherapy in epilepsy patients who completed prior study SP0994.
-
FDA approval · 2021-01-19FDA Approved: LEVETIRACETAM — Supplemental Application (Prasco Laboratories)
FDA approved a supplemental application for LEVETIRACETAM filed by Prasco Laboratories.
-
FDA approval · 2021-01-19FDA Approved: LAMOTRIGINE — Original Application (Ajanta Pharma USA Inc.)
FDA approves Ajanta Pharma USA Inc.'s original ANDA for lamotrigine, authorizing sale of a generic lamotrigine product for the same indicati…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2021-01-05Clinical Trial Update: A Study of Intravenous Perampanel in Japanese Participants With Epilepsy [Phase 2]
Phase 2 intravenous perampanel study in Japanese participants with epilepsy has completed; results posted in 2021.
-
FDA approval · 2020-12-17FDA Approved: ELEPSIA XR 1000 MG — Supplemental Application (TRIPOINT THERAPEUTICS, LLC)
FDA approved a supplemental application for ELEPSIA XR 1000 mg (levetiracetam) from Tripoint Therapeutics, LLC.
-
CLINICAL_TRIALS trial_result · 2020-12-17Clinical Trial Update: Efficacy and Safety of BGG492 as Adjunctive Treatment in Patients With Partial Onset Seizures [Phase 2]
Phase 2 trial update on BGG492 as adjunctive treatment for partial onset seizures reports efficacy and safety findings.
-
FDA approval · 2020-12-16FDA Approved: NEURONTIN — Supplemental Application (Parke-Davis Div of Pfizer Inc)
FDA approved a supplemental application for Neurontin (gabapentin) submitted by Parke-Davis Div of Pfizer Inc. The action pertains to labeli…
-
FDA approval · 2020-12-16FDA Approved: NEURONTIN — Supplemental Application (Parke-Davis Div of Pfizer Inc)
The FDA approved a supplemental application for Neurontin (gabapentin) submitted by Parke-Davis Division of Pfizer Inc, indicating a change …
-
FDA label_change · 2020-12-09FDA Approved: SYMPAZAN — Supplemental Application (Aquestive Therapeutics)
FDA approved a supplemental application for Sympazan (clobazam) from Aquestive Therapeutics, resulting in changes to the drug’s labeling/ind…
-
FDA approval · 2020-12-02FDA Approved: VIGABATRIN — Original Application (Ascend Laboratories, LLC)
FDA approved Ascend Laboratories' original ANDA for vigabatrin (generic vigabatrin). This approval makes a generic version of vigabatrin ava…
-
CLINICAL_TRIALS trial_result · 2020-12-01Clinical Trial Update: Lamotrigine Bioequivalence [Phase 4]
Phase 4 bioequivalence trial of lamotrigine completed; results posted in 2020.
-
FDA approval · 2020-11-27FDA Approved: LEVETIRACETAM ER — Original Application (Westminster Pharmaceuticals, LLC)
FDA approved Westminster Pharmaceuticals' generic extended-release levetiracetam tablet (LEVETIRACETAM ER) under an Original Abbreviated New…
-
FDA approval · 2020-11-18FDA Approved: TROKENDI XR — Supplemental Application (Supernus Pharmaceuticals, Inc.)
FDA approved a supplemental application for Trokendi XR (topiramate) from Supernus Pharmaceuticals, indicating an update to its labeling.
-
FDA approval · 2020-11-05FDA Approved: OXCARBAZEPINE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
FDA approved a supplemental application for oxcarbazepine from Sun Pharmaceutical Industries, Inc., resulting in an approved labeling change…
-
FDA approval · 2020-10-30FDA Approved: VALPROIC ACID — Supplemental Application (ANI Pharmaceuticals, Inc.)
FDA approved a supplemental application for Valproic Acid submitted by ANI Pharmaceuticals, Inc.
-
FDA approval · 2020-10-27FDA Approved: GABAPENTIN — Supplemental Application (BluePoint Laboratories)
The FDA approved a supplemental application for gabapentin from BluePoint Laboratories under an ANDA.
-
FDA approval · 2020-10-20FDA Approved: SABRIL — Supplemental Application (Lundbeck Pharmaceuticals LLC)
The FDA approved a supplemental application for Sabril (vigabatrin) submitted by Lundbeck Pharmaceuticals LLC. The action updates the approv…
-
FDA approval · 2020-10-19FDA Approved: GABAPENTIN — Supplemental Application (QUALLENT PHARMACEUTICALS HEALTH LLC)
FDA approved a supplemental application for gabapentin from Quallent Pharmaceuticals Health LLC. The approval may modify labeling or indicat…
-
CLINICAL_TRIALS trial_result · 2020-10-19Clinical Trial Update: Anxiety and Depression in Epilepsy: A Treatment Study [Phase 4]
Phase 4 clinical trial examining treatment for anxiety and depression in patients with epilepsy has completed with posted results.
-
CLINICAL_TRIALS trial_result · 2020-10-14Clinical Trial Update: Childhood Absence Epilepsy Rx PK-PD-Pharmacogenetics Study [Phase 3]
Phase 3 clinical trial update for a pediatric epilepsy study focusing on pharmacokinetics, pharmacodynamics, and pharmacogenetics in Childho…
-
FDA approval · 2020-10-09FDA Approved: LAMICTAL — Supplemental Application (GlaxoSmithKline LLC)
The FDA approved a supplemental application for Lamictal (lamotrigine) from GlaxoSmithKline LLC. The action typically involves changes to la…
-
FDA approval · 2020-10-09FDA Approved: LAMICTAL — Supplemental Application (GlaxoSmithKline LLC)
The FDA approved a supplemental application for Lamictal (lamotrigine) filed by GlaxoSmithKline, leading to changes in the product labeling.
-
FDA approval · 2020-10-09FDA Approved: LAMICTAL ODT — Supplemental Application (GlaxoSmithKline LLC)
FDA approved a supplemental application for Lamictal ODT (lamotrigine) submitted by GlaxoSmithKline LLC.